Cargando…

Provision of clinical pharmacy services in two safety net provider settings

OBJECTIVE: The purpose of this report is to characterize the patient population served by the Grace Lamsam Pharmacy Program and to describe program outcomes. METHODS: A chart review was conducted for all patients (n=100) participating in the Grace Lamsam Pharmacy Program from January 1, 2007 to Febr...

Descripción completa

Detalles Bibliográficos
Autores principales: Connor, Sharon E., Snyder, Margie E., Snyder, Zachary J., Pater Steinmetz, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139746/
https://www.ncbi.nlm.nih.gov/pubmed/25152784
_version_ 1782331405565427712
author Connor, Sharon E.
Snyder, Margie E.
Snyder, Zachary J.
Pater Steinmetz, Karen
author_facet Connor, Sharon E.
Snyder, Margie E.
Snyder, Zachary J.
Pater Steinmetz, Karen
author_sort Connor, Sharon E.
collection PubMed
description OBJECTIVE: The purpose of this report is to characterize the patient population served by the Grace Lamsam Pharmacy Program and to describe program outcomes. METHODS: A chart review was conducted for all patients (n=100) participating in the Grace Lamsam Pharmacy Program from January 1, 2007 to February 6, 2008. The primary outcome data collected were the medication related problems (unnecessary drug therapy, needs additional drug therapy, ineffective drug therapy, dosage too low, dosage too high, adverse drug reaction, noncompliance, and needs different drug product) identified by pharmacists, the number and type of pharmacist interventions made, estimated cost savings from perspective of the patient and clinical data (hemoglobin A1C, blood pressure measurements, and LDL-C) for patients with diabetes, hypertension, and hyperlipidemia, respectively. Basic demographic data was collected, including: patient gender, age, education level, race/ethnicity, marital status, and income. Patients’ smoking status, type and number of medical conditions, medications being used at baseline, and number of pharmacist visits per patient during the study review period were also recorded. RESULTS: The majority of patients cared for were male, middle-aged, and African-American. The majority (90%) of patients had an income below 150% of the 2007 Federal poverty level. Patients were most commonly treated for diabetes, hypertension, and hyperlipidemia. During the period of review, 188 medication related problems were identified and documented with noncompliance being the most common medication related problem identified. Pharmacists completed 477 Pharmaceutical Manufacturer Assistance Program applications for 68 patients. These interventions represented a cost savings from the patients’ perspective of approximately 243 USD per month during the review period. Blood pressure, A1C, and LDL-C readings improved in patients enrolled in the clinical pharmacy program at the free clinic and the community health center. CONCLUSION: A clinical pharmacy services model provides a role for the pharmacist in an interdisciplinary team (beyond the traditional dispensing role) to identify medication related problems in the drug therapy of patients who utilize safety-net provider health care services.
format Online
Article
Text
id pubmed-4139746
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-41397462014-08-22 Provision of clinical pharmacy services in two safety net provider settings Connor, Sharon E. Snyder, Margie E. Snyder, Zachary J. Pater Steinmetz, Karen Pharm Pract (Granada) Original Research OBJECTIVE: The purpose of this report is to characterize the patient population served by the Grace Lamsam Pharmacy Program and to describe program outcomes. METHODS: A chart review was conducted for all patients (n=100) participating in the Grace Lamsam Pharmacy Program from January 1, 2007 to February 6, 2008. The primary outcome data collected were the medication related problems (unnecessary drug therapy, needs additional drug therapy, ineffective drug therapy, dosage too low, dosage too high, adverse drug reaction, noncompliance, and needs different drug product) identified by pharmacists, the number and type of pharmacist interventions made, estimated cost savings from perspective of the patient and clinical data (hemoglobin A1C, blood pressure measurements, and LDL-C) for patients with diabetes, hypertension, and hyperlipidemia, respectively. Basic demographic data was collected, including: patient gender, age, education level, race/ethnicity, marital status, and income. Patients’ smoking status, type and number of medical conditions, medications being used at baseline, and number of pharmacist visits per patient during the study review period were also recorded. RESULTS: The majority of patients cared for were male, middle-aged, and African-American. The majority (90%) of patients had an income below 150% of the 2007 Federal poverty level. Patients were most commonly treated for diabetes, hypertension, and hyperlipidemia. During the period of review, 188 medication related problems were identified and documented with noncompliance being the most common medication related problem identified. Pharmacists completed 477 Pharmaceutical Manufacturer Assistance Program applications for 68 patients. These interventions represented a cost savings from the patients’ perspective of approximately 243 USD per month during the review period. Blood pressure, A1C, and LDL-C readings improved in patients enrolled in the clinical pharmacy program at the free clinic and the community health center. CONCLUSION: A clinical pharmacy services model provides a role for the pharmacist in an interdisciplinary team (beyond the traditional dispensing role) to identify medication related problems in the drug therapy of patients who utilize safety-net provider health care services. Centro de Investigaciones y Publicaciones Farmaceuticas 2009 2009-03-15 /pmc/articles/PMC4139746/ /pubmed/25152784 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Connor, Sharon E.
Snyder, Margie E.
Snyder, Zachary J.
Pater Steinmetz, Karen
Provision of clinical pharmacy services in two safety net provider settings
title Provision of clinical pharmacy services in two safety net provider settings
title_full Provision of clinical pharmacy services in two safety net provider settings
title_fullStr Provision of clinical pharmacy services in two safety net provider settings
title_full_unstemmed Provision of clinical pharmacy services in two safety net provider settings
title_short Provision of clinical pharmacy services in two safety net provider settings
title_sort provision of clinical pharmacy services in two safety net provider settings
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139746/
https://www.ncbi.nlm.nih.gov/pubmed/25152784
work_keys_str_mv AT connorsharone provisionofclinicalpharmacyservicesintwosafetynetprovidersettings
AT snydermargiee provisionofclinicalpharmacyservicesintwosafetynetprovidersettings
AT snyderzacharyj provisionofclinicalpharmacyservicesintwosafetynetprovidersettings
AT patersteinmetzkaren provisionofclinicalpharmacyservicesintwosafetynetprovidersettings